NIH, EURORDIS and more on globalizing orphan drug access at World Orphan Drug Congress USA 2013

An EU single orphan drug market with SOBI, EURORDIS and more at World Orphan Drug Congress USA 2013Подробнее

Yann Le Cam of EURORDIS on EU rare disease treatment at World Orphan Drug Congress USAПодробнее

Fabrizia Bignami (EURORDIS), speaks about 10 years of Orphan Drug regulation in Europe.Подробнее

Panel session on global patient registry status updates at World Orphan Drug Congress USA 2013Подробнее

5th EURORDIS survey on access to Orphan Drugs in EuropeПодробнее

Charles Shasky of Aetna on payers' financial planning at World Orphan Drug Congress USA 2013Подробнее

Chris Garabedian of Sarepta on personalized medicine at World Orphan Drug Congress USA 13Подробнее

World Orphan Drug Congress - who should attend?Подробнее

world orphan drug congress usa 2013- pitch and partner / expoПодробнее

A Global Update on Orphan DrugsПодробнее

Brian Malkin discusses some differences in orphan drug regulations in us vs europeПодробнее

Early access to orphan drugs -- the rationale, challenges and options available / Mark Corbett, GloПодробнее

John Maddox of Infusion Pharma Consulting on pricing at World Orphan Drug Congress USA 2013Подробнее

What can be done to support faster more equitable access to orphan medicines to patients?Подробнее

The Orphan Drug Act at 40Подробнее

Inside view: Rising to the challenges of orphan drug developmentПодробнее

Patients often face barriers to accessing the medicines their doctors prescribeПодробнее

The Role of Big Pharma in Orphan Drug Development and CommercializationПодробнее